{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T15:59:16Z","timestamp":1768319956514,"version":"3.49.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2016,5,11]],"date-time":"2016-05-11T00:00:00Z","timestamp":1462924800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"National Health & Medical Research Council of Australia (NHMRC) Project Grant"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1007\/s00125-016-3977-5","type":"journal-article","created":{"date-parts":[[2016,5,11]],"date-time":"2016-05-11T10:14:05Z","timestamp":1462961645000},"page":"1778-1790","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["The angiotensin II type 2 receptor agonist Compound 21 is protective in experimental diabetes-associated atherosclerosis"],"prefix":"10.1007","volume":"59","author":[{"given":"Bryna S. M.","family":"Chow","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Koulis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pooja","family":"Krishnaswamy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrike M.","family":"Steckelings","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Unger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark E.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karin A.","family":"Jandeleit-Dahm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terri J.","family":"Allen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,5,11]]},"reference":[{"key":"3977_CR1","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1111\/j.1476-5381.2010.00750.x","volume":"160","author":"TK Ma","year":"2010","unstructured":"Ma TK, Kam KK, Yan BP, Lam YY (2010) Renin-angiotensin-aldosterone system blockade for cardiovascular diseases: current status. Br J Pharmacol 160:1273\u20131292","journal-title":"Br J Pharmacol"},{"key":"3977_CR2","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/01.hjh.0000160198.05416.72","volume":"23","author":"KA Jandeleit-Dahm","year":"2005","unstructured":"Jandeleit-Dahm KA, Tikellis C, Reid CM, Johnston CI, Cooper ME (2005) Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes. J Hypertens 23:463\u2013473","journal-title":"J Hypertens"},{"key":"3977_CR3","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1042\/CS20110036","volume":"121","author":"S Bosnyak","year":"2011","unstructured":"Bosnyak S, Jones ES, Christopoulos A, Aguilar MI, Thomas WG, Widdop RE (2011) Relative affinity of angiotensin peptides and novel ligands at AT1 and AT2 receptors. Clin Sci (Lond) 121:297\u2013303","journal-title":"Clin Sci (Lond)"},{"key":"3977_CR4","doi-asserted-by":"crossref","first-page":"C82","DOI":"10.1152\/ajpcell.00287.2006","volume":"292","author":"PK Mehta","year":"2007","unstructured":"Mehta PK, Griendling KK (2007) Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol 292:C82\u2013C97","journal-title":"Am J Physiol Cell Physiol"},{"key":"3977_CR5","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.cardiores.2004.01.011","volume":"62","author":"O Johren","year":"2004","unstructured":"Johren O, Dendorfer A, Dominiak P (2004) Cardiovascular and renal function of angiotensin II type-2 receptors. Cardiovasc Res 62:460\u2013467","journal-title":"Cardiovasc Res"},{"key":"3977_CR6","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.1161\/CIRCULATIONAHA.105.541714","volume":"112","author":"VL Sales","year":"2005","unstructured":"Sales VL, Sukhova GK, Lopez-Ilasaca MA, Libby P, Dzau VJ, Pratt RE (2005) Angiotensin type 2 receptor is expressed in murine atherosclerotic lesions and modulates lesion evolution. Circulation 112:3328\u20133336","journal-title":"Circulation"},{"key":"3977_CR7","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3317\/jraas.2008.005","volume":"9","author":"ME Johansson","year":"2008","unstructured":"Johansson ME, Fagerberg B, Bergstrom G (2008) Angiotensin type 2 receptor is expressed in human atherosclerotic lesions. J Renin Angiotensin Aldosterone Syst 9:17\u201321","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"3977_CR8","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1161\/HYPERTENSIONAHA.111.180158","volume":"59","author":"A Rehman","year":"2012","unstructured":"Rehman A, Leibowitz A, Yamamoto N et al (2012) Angiotensin type 2 receptor agonist compound 21 reduces vascular injury and myocardial fibrosis in stroke-prone spontaneously hypertensive rats. Hypertension 59:291\u2013299","journal-title":"Hypertension"},{"key":"3977_CR9","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1161\/HYPERTENSIONAHA.110.164202","volume":"57","author":"LC Matavelli","year":"2011","unstructured":"Matavelli LC, Huang J, Siragy HM (2011) Angiotensin AT2 receptor stimulation inhibits early renal inflammation in renovascular hypertension. Hypertension 57:308\u2013313","journal-title":"Hypertension"},{"key":"3977_CR10","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1161\/HYPERTENSIONAHA.111.00422","volume":"61","author":"I Dhande","year":"2013","unstructured":"Dhande I, Ali Q, Hussain T (2013) Proximal tubule angiotensin AT2 receptors mediate an anti-inflammatory response via interleukin-10: role in renoprotection in obese rats. Hypertension 61:1218\u20131226","journal-title":"Hypertension"},{"key":"3977_CR11","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1161\/HYPERTENSIONAHA.115.05204","volume":"65","author":"C Koulis","year":"2015","unstructured":"Koulis C, Chow BS, McKelvey M et al (2015) AT2R agonist, compound 21, is reno-protective against type 1 diabetic nephropathy. Hypertension 65:1073\u20131081","journal-title":"Hypertension"},{"key":"3977_CR12","doi-asserted-by":"crossref","first-page":"5995","DOI":"10.1021\/jm049715t","volume":"47","author":"Y Wan","year":"2004","unstructured":"Wan Y, Wallinder C, Plouffe B et al (2004) Design, synthesis, and biological evaluation of the first selective nonpeptide AT2 receptor agonist. J Med Chem 47:5995\u20136008","journal-title":"J Med Chem"},{"key":"3977_CR13","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1161\/01.RES.0000266449.37396.1f","volume":"100","author":"W Hsueh","year":"2007","unstructured":"Hsueh W, Abel ED, Breslow JL et al (2007) Recipes for creating animal models of diabetic cardiovascular disease. Circ Res 100:1415\u20131427","journal-title":"Circ Res"},{"key":"3977_CR14","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1093\/ndt\/gfh499","volume":"19","author":"Q Fan","year":"2004","unstructured":"Fan Q, Liao J, Kobayashi M et al (2004) Candesartan reduced advanced glycation end-products accumulation and diminished nitro-oxidative stress in type 2 diabetic KK\/Ta mice. Nephrol Dial Transplant 19:3012\u20133020","journal-title":"Nephrol Dial Transplant"},{"key":"3977_CR15","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1161\/01.CIR.0000021122.63813.32","volume":"106","author":"R Candido","year":"2002","unstructured":"Candido R, Jandeleit-Dahm KA, Cao Z et al (2002) Prevention of accelerated atherosclerosis by angiotensin-converting enzyme inhibition in diabetic apolipoprotein E-deficient mice. Circulation 106:246\u2013253","journal-title":"Circulation"},{"key":"3977_CR16","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1042\/CS20140045","volume":"127","author":"C Koulis","year":"2014","unstructured":"Koulis C, Kanellakis P, Pickering RJ et al (2014) Role of bone-marrow- and non-bone-marrow-derived receptor for advanced glycation end-products (RAGE) in a mouse model of diabetes-associated atherosclerosis. Clin Sci (Lond) 127:485\u2013497","journal-title":"Clin Sci (Lond)"},{"key":"3977_CR17","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1161\/01.CIR.0000124061.78478.94","volume":"109","author":"R Candido","year":"2004","unstructured":"Candido R, Allen TJ, Lassila M et al (2004) Irbesartan but not amlodipine suppresses diabetes-associated atherosclerosis. Circulation 109:1536\u20131542","journal-title":"Circulation"},{"key":"3977_CR18","first-page":"56","volume":"2","author":"Y Li","year":"2012","unstructured":"Li Y, Li XH, Yuan H (2012) Angiotensin II type-2 receptor-specific effects on the cardiovascular system. Cardiovasc Diagn Ther 2:56\u201362","journal-title":"Cardiovasc Diagn Ther"},{"key":"3977_CR19","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.ijcard.2013.09.015","volume":"169","author":"ST Kljajic","year":"2013","unstructured":"Kljajic ST, Widdop RE, Vinh A et al (2013) Direct AT2 receptor stimulation is athero-protective and stabilizes plaque in apolipoprotein E-deficient mice. Int J Cardiol 169:281\u2013287","journal-title":"Int J Cardiol"},{"key":"3977_CR20","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1161\/CIRCULATIONAHA.108.784868","volume":"118","author":"E Kaschina","year":"2008","unstructured":"Kaschina E, Grzesiak A, Li J et al (2008) Angiotensin II type 2 receptor stimulation: a novel option of therapeutic interference with the renin-angiotensin system in myocardial infarction? Circulation 118:2523\u20132532","journal-title":"Circulation"},{"key":"3977_CR21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacc.2013.09.019","volume":"63","author":"AS Jaipersad","year":"2014","unstructured":"Jaipersad AS, Lip GY, Silverman S, Shantsila E (2014) The role of monocytes in angiogenesis and atherosclerosis. J Am Coll Cardiol 63:1\u201311","journal-title":"J Am Coll Cardiol"},{"key":"3977_CR22","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1083\/jcb.201412052","volume":"209","author":"I Tabas","year":"2015","unstructured":"Tabas I, Garcia-Cardena G, Owens GK (2015) Recent insights into the cellular biology of atherosclerosis. J Cell Biol 209:13\u201322","journal-title":"J Cell Biol"},{"key":"3977_CR23","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1097\/FJC.0000000000000207","volume":"65","author":"LC Matavelli","year":"2015","unstructured":"Matavelli LC, Zatz R, Siragy HM (2015) A nonpeptide angiotensin II type 2 receptor agonist prevents renal inflammation in early diabetes. J Cardiovasc Pharmacol 65:371\u2013376","journal-title":"J Cardiovasc Pharmacol"},{"key":"3977_CR24","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S0031-6997(24)01458-3","volume":"52","author":"M Gasparo de","year":"2000","unstructured":"de Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T (2000) International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 52:415\u2013472","journal-title":"Pharmacol Rev"},{"key":"3977_CR25","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1111\/j.1523-1755.1998.00893.x","volume":"53","author":"J Ma","year":"1998","unstructured":"Ma J, Nishimura H, Fogo A, Kon V, Inagami T, Ichikawa I (1998) Accelerated fibrosis and collagen deposition develop in the renal interstitium of angiotensin type 2 receptor null mutant mice during ureteral obstruction. Kidney Int 53:937\u2013944","journal-title":"Kidney Int"},{"key":"3977_CR26","doi-asserted-by":"crossref","first-page":"521076","DOI":"10.1155\/2011\/521076","volume":"2011","author":"SY Chang","year":"2011","unstructured":"Chang SY, Chen YW, Chenier I, Tran Sle M, Zhang SL (2011) Angiotensin II type II receptor deficiency accelerates the development of nephropathy in type I diabetes via oxidative stress and ACE2. Exp Diabetes Res 2011:521076","journal-title":"Exp Diabetes Res"},{"key":"3977_CR27","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1096\/fj.04-2960fje","volume":"19","author":"J Li","year":"2005","unstructured":"Li J, Culman J, Hortnagl H et al (2005) Angiotensin AT2 receptor protects against cerebral ischemia-induced neuronal injury. FASEB J 19:617\u2013619","journal-title":"FASEB J"},{"key":"3977_CR28","doi-asserted-by":"crossref","first-page":"G284","DOI":"10.1152\/ajpgi.90409.2008","volume":"296","author":"B Ulmasov","year":"2009","unstructured":"Ulmasov B, Xu Z, Tetri LH, Inagami T, Neuschwander-Tetri BA (2009) Protective role of angiotensin II type 2 receptor signaling in a mouse model of pancreatic fibrosis. Am J Physiol Gastrointest Liver Physiol 296:G284\u2013G294","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"3977_CR29","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1161\/CIRCULATIONAHA.104.525550","volume":"112","author":"M Iwai","year":"2005","unstructured":"Iwai M, Chen R, Li Z, Shiuchi T, Suzuki J et al (2005) Deletion of angiotensin II type 2 receptor exaggerated atherosclerosis in apolipoprotein E-null mice. Circulation 112:1636\u20131643","journal-title":"Circulation"},{"key":"3977_CR30","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1177\/1470320313491794","volume":"16","author":"H Takata","year":"2015","unstructured":"Takata H, Yamada H, Kawahito H et al (2015) Vascular angiotensin II type 2 receptor attenuates atherosclerosis via a kinin\/NO-dependent mechanism. J Renin Angiotensin Aldosterone Syst 16:311\u2013320","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"3977_CR31","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/sj.bjp.0704331","volume":"134","author":"A Daugherty","year":"2001","unstructured":"Daugherty A, Manning MW, Cassis LA (2001) Antagonism of AT2 receptors augments angiotensin II-induced abdominal aortic aneurysms and atherosclerosis. Br J Pharmacol 134:865\u2013870","journal-title":"Br J Pharmacol"},{"key":"3977_CR32","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.atherosclerosis.2007.11.006","volume":"199","author":"C Hu","year":"2008","unstructured":"Hu C, Dandapat A, Chen J, Liu Y, Hermonat PL, Carey RM, Mehta JL (2008) Over-expression of angiotensin II type 2 receptor (agtr2) reduces atherogenesis and modulates LOX-1, endothelial nitric oxide synthase and heme-oxygenase-1 expression. Atherosclerosis 199:288\u2013294","journal-title":"Atherosclerosis"},{"key":"3977_CR33","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1177\/1470320314561138","volume":"16","author":"T Kato","year":"2015","unstructured":"Kato T, Kawahito H, Kishida S et al (2015) Bone marrow angiotensin AT2 receptor deficiency aggravates atherosclerosis development by eliminating macrophage liver X receptor-mediated anti-atherogenic actions. J Renin Angiotensin Aldosterone Syst 16:936\u2013946","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"3977_CR34","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1007\/s00125-009-1619-x","volume":"53","author":"A Koitka","year":"2010","unstructured":"Koitka A, Cao Z, Koh P et al (2010) Angiotensin II subtype 2 receptor blockade and deficiency attenuate the development of atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes. Diabetologia 53:584\u2013592","journal-title":"Diabetologia"},{"key":"3977_CR35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0061849","volume":"8","author":"A Daugherty","year":"2013","unstructured":"Daugherty A, Rateri DL, Howatt DA, Charnigo R, Cassis LA (2013) PD123319 augments angiotensin II-induced abdominal aortic aneurysms through an AT2 receptor-independent mechanism. PLoS One 8:e61849","journal-title":"PLoS One"},{"key":"3977_CR36","doi-asserted-by":"crossref","first-page":"3849","DOI":"10.1161\/01.CIR.0000150540.54220.C4","volume":"110","author":"A Daugherty","year":"2004","unstructured":"Daugherty A, Rateri DL, Lu H, Inagami T, Cassis LA (2004) Hypercholesterolemia stimulates angiotensin peptide synthesis and contributes to atherosclerosis through the AT1A receptor. Circulation 110:3849\u20133857","journal-title":"Circulation"},{"key":"3977_CR37","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1161\/01.HYP.0000048340.53100.43","volume":"41","author":"Y Oishi","year":"2003","unstructured":"Oishi Y, Ozono R, Yano Y et al (2003) Cardioprotective role of AT2 receptor in postinfarction left ventricular remodeling. Hypertension 41:814\u2013818","journal-title":"Hypertension"},{"key":"3977_CR38","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1152\/physiolgenomics.00170.2004","volume":"19","author":"BL Falcon","year":"2004","unstructured":"Falcon BL, Stewart JM, Bourassa E et al (2004) Angiotensin II type 2 receptor gene transfer elicits cardioprotective effects in an angiotensin II infusion rat model of hypertension. Physiol Genomics 19:255\u2013261","journal-title":"Physiol Genomics"},{"key":"3977_CR39","volume":"7","author":"N Wang","year":"2012","unstructured":"Wang N, Frank GD, Ding R et al (2012) Promyelocytic leukemia zinc finger protein activates GATA4 transcription and mediates cardiac hypertrophic signaling from angiotensin II receptor 2. PLoS One 7:e35632","journal-title":"PLoS One"},{"key":"3977_CR40","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1476-5381.2009.00575.x","volume":"159","author":"S Bosnyak","year":"2010","unstructured":"Bosnyak S, Welungoda IK, Hallberg A, Alterman M, Widdop RE, Jones ES (2010) Stimulation of angiotensin AT2 receptors by the non-peptide agonist, Compound 21, evokes vasodepressor effects in conscious spontaneously hypertensive rats. Br J Pharmacol 159:709\u2013716","journal-title":"Br J Pharmacol"},{"key":"3977_CR41","doi-asserted-by":"crossref","unstructured":"Chow BS, Kocan M, Bosnyak S et al (2014) Relaxin requires the angiotensin II type 2 receptor to abrogate renal interstitial fibrosis. Kidney Int 86:75\u201385","DOI":"10.1038\/ki.2013.518"},{"key":"3977_CR42","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1161\/CIRCULATIONAHA.114.013168","volume":"131","author":"S Salem","year":"2015","unstructured":"Salem S, Jankowski V, Asare Y et al (2015) Identification of the vasoconstriction-inhibiting factor (VIF), a potent endogenous cofactor of angiotensin II Acting on the angiotensin II type 2 receptor. Circulation 131:1426\u20131434","journal-title":"Circulation"},{"key":"3977_CR43","doi-asserted-by":"crossref","first-page":"39721","DOI":"10.1074\/jbc.M105253200","volume":"276","author":"S AbdAlla","year":"2001","unstructured":"AbdAlla S, Lother H, Abdel-tawab AM, Quitterer U (2001) The angiotensin II AT2 receptor is an AT1 receptor antagonist. J Biol Chem 276:39721\u201339726","journal-title":"J Biol Chem"},{"key":"3977_CR44","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1016\/S0735-1097(98)00441-0","volume":"32","author":"A Jalowy","year":"1998","unstructured":"Jalowy A, Schulz R, Dorge H, Behrends M, Heusch G (1998) Infarct size reduction by AT1-receptor blockade through a signal cascade of AT2-receptor activation, bradykinin and prostaglandins in pigs. J Am Coll Cardiol 32:1787\u20131796","journal-title":"J Am Coll Cardiol"},{"key":"3977_CR45","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.yjmcc.2004.08.004","volume":"37","author":"ES Jones","year":"2004","unstructured":"Jones ES, Black MJ, Widdop RE (2004) Angiotensin AT2 receptor contributes to cardiovascular remodelling of aged rats during chronic AT1 receptor blockade. J Mol Cell Cardiol 37:1023\u20131030","journal-title":"J Mol Cell Cardiol"},{"key":"3977_CR46","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.bbrc.2013.10.108","volume":"441","author":"VG Barauna","year":"2013","unstructured":"Barauna VG, Mantuan PR, Magalhaes FC, Campos LC, Krieger JE (2013) AT1 receptor blocker potentiates shear-stress induced nitric oxide production via modulation of eNOS phosphorylation of residues Thr(495) and Ser(1177). Biochem Biophys Res Commun 441:713\u2013719","journal-title":"Biochem Biophys Res Commun"},{"key":"3977_CR47","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1254\/jphs.09336FP","volume":"113","author":"GX Zhang","year":"2010","unstructured":"Zhang GX, Kimura S, Murao K et al (2010) Effects of angiotensin type I receptor blockade on the cardiac Raf\/MEK\/ERK cascade activated via adrenergic receptors. J Pharmacol Sci 113:224\u2013233","journal-title":"J Pharmacol Sci"},{"key":"3977_CR48","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1161\/CIRCULATIONAHA.105.581892","volume":"112","author":"A Zuccollo","year":"2005","unstructured":"Zuccollo A, Shi C, Mastroianni R et al (2005) The thromboxane A2 receptor antagonist S18886 prevents enhanced atherogenesis caused by diabetes mellitus. Circulation 112:3001\u20133008","journal-title":"Circulation"},{"key":"3977_CR49","doi-asserted-by":"crossref","first-page":"AP143","DOI":"10.1161\/hyp.66.suppl_1.p143","volume":"66","author":"UM Steckelings","year":"2015","unstructured":"Steckelings UM, Fredgart M, Leurgans T et al (2015) Abstract P143: The angiotensin AT2 receptor agonist Compound 21 is a low affinity thromboxane A2 receptor antagonist. Hypertension 66:AP143","journal-title":"Hypertension"},{"key":"3977_CR50","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1016\/j.cellsig.2011.06.011","volume":"23","author":"ER Porrello","year":"2011","unstructured":"Porrello ER, Pfleger KD, Seeber RM et al (2011) Heteromerization of angiotensin receptors changes trafficking and arrestin recruitment profiles. Cell Signal 23:1767\u20131776","journal-title":"Cell Signal"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-016-3977-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00125-016-3977-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-016-3977-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T03:26:25Z","timestamp":1748921185000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00125-016-3977-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,11]]},"references-count":50,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["3977"],"URL":"https:\/\/doi.org\/10.1007\/s00125-016-3977-5","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"value":"0012-186X","type":"print"},{"value":"1432-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,11]]}}}